Catalyst
Slingshot members are tracking this event:
Phase 3 ABSSSI Oral-Only TLD for Omadacycline
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 17, 2017
Occurred Source:
http://investor.paratekpharma.com/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2286829
Related Projects
- Evaluating Omadacycline's success in the Phase 3 study to treat Acute Bacterial Skin Infections (ABSSSI). What's the asset worth? PRTK, CEMP Executed On: Sep 20, 2016 at 09:00 AM EDT
Related Keywords
Antibiotic, Omadacycline, Cabp, Absssi
